Want to see CNSP full AI Analyst Report?
Total Valuation
CNS Pharmaceuticals has a market cap or net worth of $7.42M. The enterprise value is $12.70M.
Market Cap$7.42M
Enterprise Value$12.70M
Share Statistics
CNS Pharmaceuticals has 1,461,449 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,461,449
Owned by Insiders26.49%
Owned by Institutions<0.01%
Financial Efficiency
CNS Pharmaceuticals’s return on equity (ROE) is -3.50 and return on invested capital (ROIC) is -329.54%.
Return on Equity (ROE)-3.50
Return on Assets (ROA)-1.84
Return on Invested Capital (ROIC)-329.54%
Return on Capital Employed (ROCE)-3.53
Revenue Per Employee0.00
Profits Per Employee-1.98M
Employee Count8
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of CNS Pharmaceuticals is ―. CNS Pharmaceuticals’s PEG ratio is 0.00159.
PE Ratio―
PS Ratio0.00
PB Ratio0.51
Price to FCF-0.17
Price to Operating Cash Flow-2.59
PEG Ratio0.00159
Income Statement
In the last 12 months, CNS Pharmaceuticals had revenue of 0.00 and earned -15.85M in profits. Earnings per share was -35.75.
Revenue0.00
Gross Profit0.00
Operating Income-15.99M
Pretax Income-15.85M
Net Income-15.85M
EBITDA-15.83M
Earnings Per Share (EPS)-35.75
Cash Flow
In the last 12 months, operating cash flow was -13.41M and capital expenditures -28.18K, giving a free cash flow of -13.44M billion.
Operating Cash Flow-13.41M
Free Cash Flow-13.44M
Free Cash Flow per Share-9.20
Dividends & Yields
CNS Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta3.52
52-Week Price Change-33.16%
50-Day Moving Average5.39
200-Day Moving Average4.61
Relative Strength Index (RSI)49.20
Average Volume (3m)3.94K
Important Dates
CNS Pharmaceuticals upcoming earnings date is Nov 18, 2026, After Close (Confirmed).
Last Earnings DateAug 12, 2026
Next Earnings DateNov 18, 2026
Ex-Dividend Date―
Financial Position
CNS Pharmaceuticals as a current ratio of 1.98, with Debt / Equity ratio of 0.00%
Current Ratio1.98
Quick Ratio1.98
Debt to Market Cap0.14
Net Debt to EBITDA0.43
Interest Coverage Ratio-1.05K
Taxes
In the past 12 months, CNS Pharmaceuticals has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
CNS Pharmaceuticals EV to EBITDA ratio is 0.29, with an EV/FCF ratio of 0.33.
EV to Sales0.00
EV to EBITDA0.29
EV to Free Cash Flow0.33
EV to Operating Cash Flow0.33
Balance Sheet
CNS Pharmaceuticals has $19.98M in cash and marketable securities with $0.00 in debt, giving a net cash position of $19.98M billion.
Cash & Marketable Securities$19.98M
Total Debt$0.00
Net Cash$19.98M
Net Cash Per Share$13.67
Tangible Book Value Per Share$10.20
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for CNS Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast88.43%